NewAmsterdam Pharma Co NV (NewAmsterdam Pharma Co NV) Interest Coverage : 0 (At Loss) (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. NewAmsterdam Pharma Co NV's Operating Income for the six months ended in Dec. 2023 was $-95.40 Mil. NewAmsterdam Pharma Co NV's Interest Expense for the six months ended in Dec. 2023 was $0.00 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. NewAmsterdam Pharma Co NV has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for NewAmsterdam Pharma Co NV's Interest Coverage or its related term are showing as below:

NAMS's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 142.97
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

NewAmsterdam Pharma Co NV Interest Coverage Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

NewAmsterdam Pharma Co NV Interest Coverage Chart

NewAmsterdam Pharma Co NV Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Interest Coverage

6.74

NewAmsterdam Pharma Co NV Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Coverage	Get a 7-Day Free Trial			-	298.99	-	-	-

Competitive Comparison of NewAmsterdam Pharma Co NV's Interest Coverage

For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NewAmsterdam Pharma Co NV's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's Interest Coverage distribution charts can be found below:

* The bar in red indicates where NewAmsterdam Pharma Co NV's Interest Coverage falls into.

NewAmsterdam Pharma Co NV Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

NewAmsterdam Pharma Co NV's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, NewAmsterdam Pharma Co NV's Interest Expense was $-7.86 Mil. Its Operating Income was $-175.11 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

NewAmsterdam Pharma Co NV did not have earnings to cover the interest expense.

NewAmsterdam Pharma Co NV's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the six months ended in Dec. 2023, NewAmsterdam Pharma Co NV's Interest Expense was $0.00 Mil. Its Operating Income was $-95.40 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

The higher the ratio, the stronger the company's Financial Strength is.

NewAmsterdam Pharma Co NV (NAS:NAMS) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

NewAmsterdam Pharma Co NV Interest Coverage Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

NewAmsterdam Pharma Co NV (NewAmsterdam Pharma Co NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

KH6:Germany

Address

Gooimeer 2-35, Naarden, NH, NLD, 1411 DC

Website

https://www.newamsterdampharma.com

NewAmsterdam Pharma Co NV is a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases and Alzheimer's disease.